Jim Cramer on Bristol-Myers: “Never Seen it This Cheap”

Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the lightning round, Cramer replied that he is holding out hope for the company’s “central nervous system drug.”

“Bristol Myers, never seen it this cheap. We’re holding it. I did have high hopes for their, what, what I would say is their central nervous system drug. It better work. If it doesn’t work, we’re going to get rid of it, and it will be a disappointment, and it will be a shame.”

Jim Cramer on Bristol-Myers: "Never Seen it This Cheap"

Bristol-Myers (NYSE:BMY) develops and markets biopharmaceutical products targeting cancer, cardiovascular conditions, immune disorders, and neurological diseases. The company’s portfolio includes Eliquis, Opdivo, Revlimid, and other treatments for serious and chronic illnesses. During a June episode, Cramer showed disappointment in the stock, as he commented:

“Bristol Myers, Charitable Trust owns it. So far, we’re not happy with COBENFY. It’s a little disappointing. We need to see that stock back up at 60.”

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.